Med-tech deal values the first seven months of the year are up more than 50% from last year. Meanwhile, M&As decreased almost 70% from the same time period in 2022.
Med-tech companies raised $955 million from 40 transactions in July 2023, a decrease of 12.39% from the $1.09 billion raised in July 2022. The volume of med-tech financings has increased from 32 in July 2022, though it is less than the previous six months’ average of 43 and seven-month average of 42. Compared to prior years, July 2021 saw $4.78 billion raised in 74 financings, $3.15 billion from 80 transactions in July 2020 and $1.99 billion from 41 financings in July 2019.
It only took a couple of billion-dollar transactions in the second quarter (Q2) of 2023 to push med-tech dealmaking values above all other recent years. Despite the surge in value, the volume of deals is level with other quarters.
While med-tech financings in the second quarter (Q2) rose by 24% over the first quarter (Q1) – an historically low Q1 – the overall funding landscape in 2023 has struggled to keep up with other years, with IPOs in particular hitting rock bottom. A total of $5.8 billion was raised in Q2 through 128 transactions. Combined with Q1, the amount for the first half of 2023 is $10.5 billion through 255 transactions. This is an overall drop in value during the first six months of 31% compared with the same timeframe in 2022. It also is down from 2017 – the next lowest year – by 22%.